Lagatar24 Desk
New Delhi, Jan 28: Bharat Biotech has received authorization from the Drugs Controller General of India (DCGI) to conduct trials of their intranasal Covid-19 booster dose in India. The trials will involve 900 people.
Bharat Biotech received ‘in-principle’ clearance from DCGI’s Subject Expert Committee (SEC) for the ‘phase-III booster dose trial’ for its intranasal Covid-19 vaccine, a first in India, and was asked to submit protocols for approval three weeks ago.
Notably in India, Bharat Biotech is the second company to apply for the phase-III trial of the third dose. According to reports, the intranasal vaccines have the ability to inhibit transmission of novel Covid-19 forms like Omicron.
Covidshield, Covaxin, and Sputnik V have been licenced for immunisation in India. Covaxin is approved for use under DCGI’s 28-day Multi-Dose Vial Policy (MDVP) and the World Health Organization’s Emergency Use Listing (WHO EUL).
